The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligands binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.